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ABSTRACT
This study aimed to investigate whether initial treatment of experimental pulmonary aspergillosis with
high loading doses can be used as an alternative to standard therapeutic regimens. Steroid-
immunosuppressed rats, infected intratracheally with Aspergillus fumigatus, received either amphoter-
icin B deoxycholate (d-AmB) 1 mg ⁄ kg ⁄day, liposomal amphotericin B (L-AmB) 5 mg ⁄kg ⁄day, or
underwent a 3-day course of L-AmB 10 mg ⁄ kg, or 10 mg ⁄ kg for the ﬁrst 3 or 4 days of treatment,
followed by 3 mg ⁄kg until the end of treatment. Therapy started 24 h after fungal challenge and lasted
for 7 days. Compared to controls, survival was improved signiﬁcantly in animals receiving any L-AmB
regimen (p £ 0.003), but not d-AmB. Compared with d-AmB, L-AmB at initial doses of 10 mg ⁄ kg
followed by 3 mg ⁄kg ⁄day was consistently more effective, but only when measured in terms of survival,
lung weight and glucosamine levels, and not log CFU. Despite the absence of signiﬁcant differences
between any of the L-AmB regimens, a trend towards better response rates with the higher loading dose
was observed.
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INTRODUCTION
Liposomal amphotericin B (L-AmB) has become a
therapeutic alternative to amphotericin B deo-
xycholate (d-AmB) for the treatment of invasive
pulmonary aspergillosis (IPA), which is an infec-
tion that is generally lethal when left untreated [1].
Current recommendations for the treatment of
systemic aspergillosis include the use of d-AmB
1–1.5 mg ⁄kg ⁄day, L-AmB 5 mg ⁄ kg ⁄day, or voric-
onazole, as ﬁrst-line therapy, with caspofungin as
an alternative [2–4]. However, there is still a need
for new strategies in the treatment of invasive
aspergillosis in order to diminish the current high
rates of therapeutic failure. The maximum dose of
d-AmB recommended for administration to
humans is 1.5 mg ⁄kg ⁄day because of intolerance
and other adverse effects [5]; however, L-AmB has
lower toxicity than d-AmB, thus allowing the
infusion of signiﬁcantly higher doses. Animal
models of invasive aspergillosis have shown
outcome beneﬁts (i.e., increased survival, reduc-
tion of fungal load) with the use of L-AmB
10 mg ⁄ kg ⁄day [6–8]. A recent study conducted
in humans found that doses up to 15 mg ⁄ kg were
safe andwell-tolerated [9], and preliminary results
from a pilot prospective open-label study have
shown that L-AmB 10 mg ⁄ kg ⁄day may be a safe
and effective alternative for the management of
invasive aspergillosis in immunocompromised
patients (43rd Interscience Conference on Antimi-
crobial Agents and Chemotherapy, Chicago, 2003,
abstract M-966).
In addition to reduced toxicity, the incorpor-
ation of amphotericin B into lipid vesicles [10] has
modiﬁed the pharmacokinetics of the drug with
respect to the conventional deoxycholate-associ-
ated formulation of amphotericin B [11], although
the impact of these changes on the treatment of
lung infection by Aspergillus fumigatus is still
Corresponding author and reprint requests: J. Gavalda` Santa-
pau, Servei de Malalties Infeccioses, Hospital Universitari Vall
d’Hebron, Universitat Auto`noma de Barcelona, Pg. Vall
d’Hebron 119–129, 08035 Barcelona, Spain
E-mail: address: jogavalda@vhebron.net
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
unknown. Moreover, it has been suggested that
the pharmacokinetic proﬁle means that an
improved treatment outcome might be achieved
with administration of high loading doses [12].
The present experimental study investigated whe-
ther initiating treatment for IPA with L-AmB
10 mg ⁄ kg, a level associated with maximum
plasma concentrations in humans [9], and then
continuing with lower doses, may represent an
alternative to the classical treatment with d-AmB
1 mg ⁄ kg ⁄day. In addition, the efﬁcacy of initial
high doses followed by low doses was compared
with that of L-AmB 5 mg ⁄kg ⁄day in a steroid-
immunosuppressed rat model of infection.
MATERIALS AND METHODS
Strain
A clinical isolate of A. fumigatus, strain AFJJ (deposited at the
National Centre for Microbiology, Instituto de Salud Carlos III,
Madrid, Spain) was used throughout the study. The strain was
maintained on Sabouraud dextrose agar (SDA) slants at ) 80C.
The susceptibility of this strain to amphotericin B was 1 mg ⁄L
when determined according to NCCLS guidelines [13].
Animals
Female SPF Wistar rats weighing 180–200 g (Harland Iberica,
Barcelona, Spain) were housed in cages with HEPA ﬁlters and
fed with a protein 8% w ⁄w diet and sterile water ad libitum.
The experimental protocol was approved by the Ethics
Committee of Vall d’Hebron Hospitals and the Autonomous
Government of Catalonia.
Animal model
The studywas carried out in an animal model of IPA, described
previously [14]. Brieﬂy, animals were immunosuppressed with
subcutaneous cortisone acetate 125 mg ⁄ kg (Sigma, St Louis,
MO, USA) three times ⁄week, starting 14 days before the fungal
challenge and continuing to the end of the experiment. To
avoid bacterial superinfection during immunosuppression, rats
were given colistin 2500 IU ⁄mL in drinking water, and cefep-
ime 150 mg ⁄ kg twice-daily subcutaneously. Four days before
the infection, a sterile silastic catheter connected to a subcuta-
neous port was inserted surgically through the right jugular
vein into the inferior cava vein for the administration of
antifungal treatment [15]. All surgical procedures were per-
formed under general anaesthesia (ketamine 100 mg ⁄kg plus
xylazine 10 mg ⁄ kg, intramuscularly).
After six doses of steroids (day 0), rats were infected via a
tracheotomy with 0.3 mL of a freshly prepared conidial
suspension harvested from a subculture of the A. fumigatus
strain grown on SDA plates. Conidia were harvested with a
sterile pipette by ﬂooding the plates with sterile saline
containing Tween-20 0.025% v ⁄v. The resulting suspension
was washed in sterile phosphate-buffered saline, counted in a
haemocytometer, and adjusted in sterile saline to a ﬁnal
concentration of 8 · 106 conidia ⁄mL. Serial ten-fold dilutions
were plated on to SDA plates for assessment of purity, size and
viability of the inoculum. At least 95% of conidia in the
inoculum were viable as assessed by colony counts.
Antifungal therapy
Eight doses of antifungal treatment were administered intra-
venously, starting 24 h after infection. Animals were assigned
randomly to receive either dextrose 5% w ⁄v (control, n = 52),
d-AmB (Fungizone; Bristol-Myers Squibb Group, Barcelona,
Spain) 1 mg ⁄ kg ⁄day (n = 28), L-AmB (AmBisome, Gilead
Sciences, Madrid, Spain) 5 mg ⁄ kg ⁄day (n = 33), L-AmB
10 mg ⁄ kg ⁄day for 3 days (n = 34), or L-AmB 10 mg ⁄ kg ⁄day
for 3 days (n = 34) or 4 days (n = 21), followed by L-AmB
3 mg ⁄ kg ⁄day until the end of treatment. Antifungal drugs
were prepared immediately before use, according to the
manufacturers’ instructions.
Assessment of antifungal efﬁcacy
Animals were inspected every 4 h from 08.00 h to 00.00 h,
and mortality was recorded throughout the experiment.
Surviving rats were killed humanely 24 h after the last dose
of antifungal treatment. Animals were dissected immediately
after death. Lungs were removed aseptically, weighed and
homogenised in 10 mL of sterile distilled water for 15 s with
a tissue homogeniser (Ultraturrax T25 basic; IKA Labortech-
nik, Staufen, Germany). Aliquots (500 lL) of homogenates
were diluted serially and plated on to SDA and trypticase soy
blood agar plates to assess fungal growth quantitatively and
to rule out bacterial superinfection. Data from animals dying
during the night could introduce a confounding factor in
post-mortem multiplication, although this factor was equal in
all groups.
Lung homogenates were processed for chitin assays to
quantify the fungal burden in lungs [16]. With this technique,
chitin is depolymerised, deaminated and deacetylated to gluco-
saminemonomers [17]. In brief, homogenateswere centrifuged,
resuspended in 4 mL of 0.1 M sodium lauryl sulphate (Sigma),
heated at 100C for 15 min and left to cool. Pellets were washed
indistilledwater, resuspended in 3 mLof 21.39 MKOH(Sigma)
and heated at 130C for 1 h. After addition of 8 mL of ice-cold
ethanol 75% v ⁄v, tubes were kept in ice-cold water for 15 min,
and then 0.3 mL of a suspension of diatomaceous earth (Celite
545, Sigma) in ethanol 75% v ⁄vwas added. Pelletswerewashed
once with ice-cold ethanol 40% v ⁄v, and twice with distilled
water. The supernatants were discarded, the resultant pellets
were resuspended in distilled water to a volume of 0.5 mL, and
0.5 mL of 0.72 M NaNO2 and 0.5 mL of 0.37 M KHSO4 were
then added. The tubes were centrifuged and volumes of the
supernatants were mixed with 0.2 mL of 1.1 M ammonium
sulphamate, followed by 0.2 mL of 3-methylbenzothiazolone
hydrazone hydrochloridemonohydrate (Sigma), and heated for
3 min. The supernatants were left to cool, 0.2 mL of 0.03 M
FeCl3.6H2O was added, and the optical density was read in a
spectrophotometer (UV-160A; Shimadzu Corp., Kyoto, Japan)
at 650 nm after 25 min.
Statistical analysis
Survival was analysed with Kaplan–Meier plots and the log-
rank test. Lung weight (g), pulmonary chitin content (log10 lg
glucosamine ⁄paired lungs) and log10 CFU were compared
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using the Mann–Whitney U-test. Unless indicated otherwise,
results were expressed as the mean and 95% CI of the mean,
with p £ 0.05 considered signiﬁcant.
No correction for multiple comparisons was used.
RESULTS
Data from the four experiments performed
were pooled, as no statistically signiﬁcant differ-
ences were found between the controls of each
experiment.
Survival of animals receiving antifungal treat-
ment was improved compared with the control
group, with signiﬁcant differences for groups
receiving L-AmB treatment: p < 0.003 for L-AmB
5 mg ⁄ kg ⁄day and L-AmB 10 mg ⁄ kg ⁄day for
3 days (Fig. 1); p < 0.002 and p < 0.001, respec-
tively, for L-AmB 10 mg ⁄kg ⁄day for 3 or 4 days,
followed by 3 mg ⁄ kg ⁄day until the end of
treatment. No differences were found between
the L-AmB-based regimens; however, L-AmB
10 mg ⁄ kg ⁄day for 4 days followed by
3 mg ⁄ kg ⁄day was the only regimen that resulted
in signiﬁcantly increased survival with respect to
the d-AmB regimen (p < 0.009).
Results observed in animals that survived
‡ 5 days of antifungal treatment are summarised
in Table 1. There was a signiﬁcant reduction in
lung weight, which is a marker of fungus-related
tissue injury, in all the groups receiving L-AmB
when compared with the controls (p 0.001 for
L-AmB 5 mg ⁄ kg ⁄day; p < 0.001 for L-AmB
10 mg ⁄ kg ⁄day for 3 days, and for L-AmB
10 mg ⁄ kg ⁄day for 3 or 4 days, followed by
3 mg ⁄ kg ⁄day). Again, although there were no
differences between the groups receiving L-AmB
5 mg ⁄ kg ⁄day throughout and those receiving
high loading doses, the lung weights of the
animals in the groups given L-AmB
10 mg ⁄ kg ⁄day for 3 or 4 days, followed by
3 mg ⁄ kg until the end of the experiment, were
signiﬁcantly lower than those of animals receiv-
ing d-AmB (p 0.016 and p 0.009, respectively).
With respect to fungal load, the chitin content in
the lungs was found to be lower in rats receiving
antifungal treatment than in controls. Statistically
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Fig. 1. Effect of amphotericin B deoxycholate (d-AmB) vs.
different regimens of liposomal amphotericin B (L-AmB) or
control on the cumulative survival of steroid-immunosup-
pressed rats with invasive pulmonary aspergillosis. Filled
squares, control; ﬁlled triangles, d-AmB 1 mg ⁄kg ⁄day;
ﬁlled diamonds, L-AmB 5 mg ⁄ kg ⁄day; open squares,
L-AmB 10 mg ⁄ kg ⁄day for 3 days; open circles, L-AmB
10 mg ⁄ kg ⁄day for 3 days, followed by L-AmB
3 mg ⁄kg ⁄day; open triangles, L-AmB 10 mg ⁄ kg ⁄day for
4 days, followed by L-AmB 3 mg ⁄ kg ⁄day.
Table 1. Results obtained with the different treatment groups
Group Total
Survival:
mean (95% CI)
Animals surviving treatment for ‡ 5 days
n (%)
Weight of paired lungs (g):
mean (95% CI)
Log10 lg glucosamine/
paired lungs: mean (95% CI)
Log10 CFU/g of lungs:
mean (95% CI)
Control 52 5.60 (4.90–6.29) 23 (44.23) 2.87 (2.42–3.31) 2.11 (1.87–2.35) 5.40 (5.17–5.62)
d-AmB 1 mg ⁄ kg ⁄day 28 7.00 (6.14–7.86) 21 (75) 2.30 (1.91–2.69) 2.06 (1.82–2.30) 5.19 (4.93–5.44)
L-AmB 5 mg ⁄ kg ⁄day 33 7.33 (6.56–8.10)a 25 (75.76) 1.87 (1.56–2.19)a 1.88 (1.61–2.15) 5.22 (5.01–5.44)
L-AmB 10 mg ⁄ kg ⁄day for 3 days 34 7.24 (6.42–8.05)a 25 (73.53) 1.84 (1.57–2.10)a 1.97 (1.69–2.24) 5.22 (4.94–5.51)
L-AmB 10 mg ⁄ kg ⁄day
for 3 days + 3 mg ⁄ kg ⁄dayb
34 7.44 (6.61–8.27)a 27 (79.41) 1.76 (1.43–2.10)a,c 1.74 (1.49–1.99)a 5.18 (4.99–5.37)
L-AmB 10 mg ⁄ kg ⁄
day for 4 days + 3 mg ⁄ kg ⁄dayd
21 8.14 (7.39–8.89)a,c 18 (85.71) 1.61 (1.31–1.91a,c 1.59 (1.29–1.90)a,c 5.02 (4.74–5.31)a
L-AmB, liposomal aphotericin B; d-AmB, amphotericin B deoxycholate.
ap £ 0.05 with respect to controls.
bL-AmB 10 mg ⁄ kg ⁄day for 3 days, followed by 3 mg ⁄ kg ⁄day until the end of therapy.
cp £ 0.05 with respect to d-AmB 1 mg ⁄ kg ⁄day.
dL-AmB 10 mg ⁄ kg ⁄day for 4 days, followed by 3 mg ⁄ kg ⁄day until the end of therapy.
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signiﬁcant differences with respect to the controls
were evident only in groups that received doses
of L-AmB 10 mg ⁄ kg ⁄day for the ﬁrst 3 (p 0.020)
or 4 (p 0.009) days, followed by 3 mg ⁄kg ⁄day, but
only the latter was signiﬁcantly different from the
d-AmB group (p 0.028). Outcome in the group in
which L-AmB was suspended after 3 days tended
to be poorer than in the animals that continued to
receive low doses of L-AmB to the end of
treatment, but no signiﬁcant differences were
found among these groups. As summarised in
Table 1, the CFU ⁄ g of lung count was similar in
nearly all the groups. Nevertheless, colony counts
were signiﬁcantly lower in animals that had
received L-AmB 10 mg ⁄kg ⁄day for the ﬁrst
4 days, plus 3 mg ⁄kg ⁄day until the end of treat-
ment, than in controls (p 0.048).
DISCUSSION
The aim of this study was to determine whether
initiating treatment for IPA with high doses of
L-AmB and continuing with lower doses is a valid
alternative to conventional regimens, i.e., admin-
istration of d-AmB 1 mg ⁄ kg ⁄day or L-AmB
5 mg ⁄ kg ⁄day. The initial dose of L-AmB was
10 mg ⁄ kg ⁄day, which has been shown to yield
the maximum plasma Cmax, AUC24 and AUC¥
values in humans [9]. Experimental models of IPA
using neutropenic and steroid-immunosup-
pressed rats have shown that this dosage is effect-
ive in increasing survival, reducing fungal load
and pulmonary damage [6–8], and preventing
fungal dissemination [7]. Administration of this
dosewas limited to amaximumof 4 days, based on
a previous observation that use of this dose for
‡ 5 days in uninfected steroid-treated animals pro-
duces a drug interaction causing toxicity of
unknown origin that contributes to the mortality,
whereas lower doses do not have this effect [8].
Kisch et al. [18] reported in 1978 that co-adminis-
tration of d-AmB and cortisone acetate produced
renal lesions that were dose-related in severity, but
there appears to be no similar information relating
to L-AmB in the scientiﬁc literature.
The indications of the therapeutic efﬁcacy of
high loading doses of L-AmB were two-fold. First,
in the steroid-immunosuppressed murine model
of IPA, the use of d-AmB 1 mg ⁄ kg ⁄day did not
improve the outcome of the infection compared
with the controls, whereas any of the studied
regimens involving administration of L-AmB
achieved statistically signiﬁcant differences in at
least one of the four parameters examined com-
pared with the controls. This is consistent with
previous work, in which the efﬁcacy of
‡ 5 mg ⁄ kg ⁄day of L-AmB has been observed [8].
Equivalent improved efﬁcacy of ‡ 5 mg ⁄ kg ⁄day of
L-AmB compared with the conventional formula-
tion has been reported in animal models of inva-
sive aspergillosis [6,7], although in humans, the
superiority of relatively high doses of L-AmB
(i.e., up to 4 mg ⁄ kg ⁄day) over d-AmB (up to
1.5 mg ⁄kg ⁄day) is still a topic of debate [19]
because of difﬁculties in design, development
and comparison of clinical trials. Interpretation of
results involving the use of L-AmBare complicated
further by the reported substantial inter-patient
differences in the handling of this drug [20].
Second, despite the absence of differences in
outcome between the various L-AmB regimens
used in this study, a slight trend towards better
results was observed in groups receiving a com-
bination of loading doses followed by low doses
of L-AmB, with prolonged administration of high
loading doses followed by lower doses resulting
in signiﬁcant differences in survival, reduction of
lung weight and glucosamine content compared
with d-AmB 1 mg ⁄ kg ⁄day. This was in contrast
with the results obtained with L-AmB
5 mg ⁄ kg ⁄day, but is in keeping with the ﬁndings
of Becker et al. [21], who showed an improvement
in survival and pulmonary fungal load in a
neutropenic rat model of IPA with the use of
another type of intensive initial therapy involving
the addition of d-AmB on the ﬁrst day of therapy
with high doses of L-AmB.
In contrast to the results for survival, lung
weight and lung glucosamine content, CFU
counts did not vary signiﬁcantly between the
treatment groups, with the exception indicated in
Table 1. This may be because CFU counts do not
represent the real viable fungal load, as larger
hyphae represent a larger fungal load, but not
necessarily a larger number of CFUs [6,21].
The use of initial high doses for treating IPA
represents an aggressive approach to therapy for
this infection, the importance of which has been
noted previously [21–23]. Although no substan-
tive differences were found between the outcomes
with any of the L-AmB regimens in the present
experimental model of IPA, a trend towards
a slightly better outcome was seen with the
higher loading dose. The clinical meaning of this
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observation remains to be determined, and cau-
tion in interpreting this result is required until
further studies are conducted. However, prelim-
inary results from a non-comparative study have
shown that a primary treatment period consisting
of 5 days of L-AmB 10 mg ⁄kg ⁄day, followed by
9 days of L-AmB 3 mg ⁄ kg ⁄day, yields an overall
response rate (both partial and complete) of 60%
in patients with proven or probable invasive
fungal infection or chronic disseminated candidi-
asis (Annual Scientiﬁc Meeting of the British
Society for Haematology, Cardiff, 2004, abstract
202). The present study was not designed to
determine the exact duration of initial therapy
with high doses, and the suggested approach to
treatment of IPA with loading doses should be the
subject of in-depth investigations in other models
of experimental IPA.
In conclusion, the use of initial high loading
doses appears to be a valid alternative to d-AmB
1 mg ⁄kg ⁄day in the steroid-immunosuppressed
model of IPA, with an efﬁcacy that is at least
equivalent to that of L-AmB 5 mg ⁄ kg ⁄day. The
duration of the initial high doses cannot be
deduced from the ﬁndings in this study, and
further work is required on this subject.
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